Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art

References

• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280.
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762. .
   PubMed Web of Science ®Google Scholar
• Nakeeb A, Lipsett PA, Lillemoe KD, et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg. 1996;171(1):147–152. discussion152-143. .
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588.
   PubMed Web of Science ®Google Scholar
• Buckholz AP, Brown RS Jr. Cholangiocarcinoma: diagnosis and management. Clin Liver Dis. 2020;24(3):421–436.
   PubMed Web of Science ®Google Scholar
• Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol. 2019;132:42–47.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. .
   PubMed Web of Science ®Google Scholar
• Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a Phase 2 clinical trial. JAMA Oncol. 2019;6(1):60-67.
   Web of Science ®Google Scholar
• Buttner S, Galjart B, Beumer BR, et al. Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. HPB (Oxford). 2020;23(1):25–36. .
   PubMed Web of Science ®Google Scholar
• Mizuno T, Ebata T, Yokoyama Y, et al. Combined vascular resection for locally advanced Perihilar Cholangiocarcinoma. Ann Surg. 2020; 10.1097/SLA.0000000000004322.
   Web of Science ®Google Scholar
• Strijker M, Belkouz A, Van Der Geest LG, van der Geest LG et al. . Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58(7):1048–1055.
   PubMed Web of Science ®Google Scholar
• Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213–221.
   PubMed Web of Science ®Google Scholar
• Santoli D, Koprowski H. Mechanisms of activation of human natural killer cells against tumor and virus-infected cells. Immunol Rev. 1979;44(1):125–163.
   PubMed Web of Science ®Google Scholar
• Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18(8):862–867.
   PubMed Web of Science ®Google Scholar
• Liang B, Zhong L, He Q, et al. Diagnostic accuracy of serum CA19-9 in patients with Cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit. 2015;21:3555–3563.
   PubMed Web of Science ®Google Scholar
• Macias RIR, Kornek M, Rodrigues PM, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):108–122. .
   PubMed Web of Science ®Google Scholar
• Bolm L, Petrova E, Weitz J, et al. Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB (Oxford). 2019;21(11):1513–1519. .
   PubMed Web of Science ®Google Scholar
• Cai WK, Lin JJ, He GH, et al. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol. 2014;7(11):7890–7898.
   PubMed Web of Science ®Google Scholar
• Juntermanns B, Kaiser GM, Itani Gutierrez S, et al. [CA19-9 in intrahepatic cholangiocarcinoma: a diagnostic and prognostic armamentarium?]. Chirurg. 2018;89(6):466–471. .
   PubMed Web of Science ®Google Scholar
• Kondo N, Murakami Y, Uemura K, et al. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014;110(4):422–429. .
   PubMed Web of Science ®Google Scholar
• Yamashita S, Passot G, Aloia TA, et al., Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 104(3): 267–277. 2017.
   PubMed Web of Science ®Google Scholar
• Lee BS, Lee SH, Son JH, et al. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2016;31(2):493–500.
   PubMed Web of Science ®Google Scholar
• Fang T, Wang H, Wang Y, et al. Clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the resectability of Cholangiocarcinoma. Dis Markers. 2019;6016931:2019.
   Google Scholar
• Ince AT, Yildiz K, Baysal B, et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Turk J Gastroenterol. 2014;25(2):162–169.
   PubMed Web of Science ®Google Scholar
• Li Y, Li DJ, Chen J, et al. Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of Cholangiocarcinoma. Asian Pac J Cancer Prev. 2015;16(8):3451–3455. .
   PubMedGoogle Scholar
• Qiu Y, He J, Chen X, et al. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. Clin Chim Acta. 2018;480:186–192.
   PubMed Web of Science ®Google Scholar
• Luo X, Yuan L, Wang Y, et al. Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg. 2014;18(3):562–572.
   PubMed Web of Science ®Google Scholar
• Qiang Z, Zhang W, Jin S, et al. Carcinoembryonic antigen, alpha-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: a retrospective cohort study. Ann Hepatol. 2020;20:100242.
   PubMed Web of Science ®Google Scholar
• Moro A, Mehta R, Sahara K, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27(8):2888–2901. .
   PubMed Web of Science ®Google Scholar
• He C, Zhang Y, Song Y, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer. 2018;9(17):3117–3128. .
   PubMed Web of Science ®Google Scholar
• Loosen SH, Roderburg C, Kauertz KL, et al. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 2017;7(1):16975. .
   PubMed Web of Science ®Google Scholar
• Higashi M, Yamada N, Yokoyama S, et al. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 2012;79(2):101–106. .
   PubMed Web of Science ®Google Scholar
• Li Y, Huang Y, Chen J. Diagnostic value of serum biomarkers for Intrahepatic Cholangiocarcinoma. J Coll Physicians Surg Pak. 2019;29(10):962–966.
   PubMed Web of Science ®Google Scholar
• Guowei H, Yuan L, Ma L, et al. The diagnostic efficacy of CYFRA21-1 on intrahepatic cholangiocarcinoma: a meta-analysis. Clin Res Hepatol Gastroenterol. 2019;43(3):266–272. .
   PubMed Web of Science ®Google Scholar
• Huang L, Chen W, Liang P, et al. Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma. Dig Dis Sci. 2015;60(5):1273–1283. .
   PubMed Web of Science ®Google Scholar
• Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15(2):583–589. .
   PubMed Web of Science ®Google Scholar
• Itatsu K, Zen Y, Ohira S, et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int. 2007;27(9):1174–1184. .
   PubMed Web of Science ®Google Scholar
• Leelawat K, Narong S, Wannaprasert J, et al. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol. 2010;16(37):4697–4703.
   PubMed Web of Science ®Google Scholar
• Hirashita T, Iwashita Y, Ohta M, et al. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2012;16(4):842–848. .
   PubMed Web of Science ®Google Scholar
• Itatsu K, Zen Y, Yamaguchi J, et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol. 2008;39(5):710–719. .
   PubMed Web of Science ®Google Scholar
• Terashi T, Aishima S, Taguchi K, et al. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int. 2004;24(1):38–45. .
   PubMed Web of Science ®Google Scholar
• Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology. 2013;58(6):1992–2000. .
   PubMed Web of Science ®Google Scholar
• Loosen SH, Roderburg C, Kauertz KL, et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J Hepatol. 2017;67(4):749–757. .
   PubMed Web of Science ®Google Scholar
• Zhou KQ, Liu WF, Yang LX, et al. Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2019;8(6):582–596. .
   PubMed Web of Science ®Google Scholar
• Thummarati P, Wijitburaphat S, Prasopthum A, et al. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol. 2012;18(3):244–250. .
   PubMed Web of Science ®Google Scholar
• Grunnet M, Christensen IJ, Lassen U, et al. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clin Biochem. 2014;47(7–8):599–604. .
   PubMed Web of Science ®Google Scholar
• Loosen SH, Breuer A, Tacke F, et al. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer. JHEP Rep. 2020;2(2):100080. .
   PubMedGoogle Scholar
• Gerhardt T, Milz S, Schepke M, et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol. 2006;12(34):5495–5500. .
   PubMed Web of Science ®Google Scholar
• Onsurathum S, Haonon O, Pinlaor P, et al. Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma. Tumour Biol. 2018;40(4):1010428318767195. .
   Google Scholar
• Ruzzenente A, Iacono C, Conci S, et al. A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC). Surgery. 2014;155(4):633–639. .
   PubMed Web of Science ®Google Scholar
• Tshering G, Dorji PW, Chaijaroenkul W, et al. Biomarkers for the Diagnosis of Cholangiocarcinoma: a Systematic Review. Am J Trop Med Hyg. 2018;98(6):1788–1797.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Benz F, Niedeggen J, et al. Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clin Transl Med. 2016;5(1):39. .
   PubMedGoogle Scholar
• Tsilimigras DI, Moris D, Mehta R, et al. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB (Oxford). 2020;22(12):1667–1674. .
   PubMed Web of Science ®Google Scholar
• Huang H, Wan X, Bai Y, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma. Cancer Manag Res. 2019;11:5157–5162.
   PubMed Web of Science ®Google Scholar
• Ji F, Kang Q, Wang L, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarcinoma patients. Medicine (Baltimore). 2020;99(43):e22827. .
   PubMed Web of Science ®Google Scholar
• Lee BS, Lee SH, Son JH, et al. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65(2):141–150. .
   PubMed Web of Science ®Google Scholar
• Hu G, Liu Q, Ma JY, et al. Prognostic significance of Platelet-to-Lymphocyte Ratio in Cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2018;2018:7375169.
   PubMed Web of Science ®Google Scholar
• Huh G, Ryu JK, Chun JW, et al. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. BMC Cancer. 2020;20(1):907. .
   PubMed Web of Science ®Google Scholar
• Kano H, Midorikawa Y, Song P, et al. High C-reactive protein/albumin ratio associated with reduced survival due to advanced stage of intrahepatic cholangiocarcinoma. Biosci Trends. 2020;14(4):304–309. .
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Itoh S, Yoshizumi T, et al. C-reactive protein: albumin ratio in patients with resectable intrahepatic cholangiocarcinoma. BJS Open. 2020;4(6):1146–1152. .
   Web of Science ®Google Scholar
• Yasukawa K, Shimizu A, Motoyama H, et al. Preoperative C-reactive protein-to-albumin ratio predicts long-term outcomes in extrahepatic cholangiocarcinoma patients. J Surg Oncol. 2020;122(7):1516–1517. .
   Web of Science ®Google Scholar
• Saito H, Noji T, Okamura K, et al. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery. 2016;159(3):842–851.
   PubMed Web of Science ®Google Scholar
• Sellers CM, Uhlig J, Ludwig JM, et al. Inflammatory markers in intrahepatic cholangiocarcinoma: effects of advanced liver disease. Cancer Med. 2019;8(13):5916–5929.
   PubMed Web of Science ®Google Scholar
• Goeppert B, Frauenschuh L, Zucknick M, et al., Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 109(10): 2665–2674. 2013. .
   PubMed Web of Science ®Google Scholar
• Vigano L, Soldani C, Franceschini B, et al. Tumor-Infiltrating lymphocytes and macrophages in Intrahepatic Cholangiocellular carcinoma. Impact on prognosis after complete surgery. J Gastrointest Surg. 2019;23(11):2216–2224. .
   PubMed Web of Science ®Google Scholar
• Wu ZY, Shen W, Yue JQ, et al. Combining Immunoscore with clinicopathologic features in Cholangiocarcinoma: an Influential prognostic nomogram. Onco Targets Ther. 2020;13:11359–11376.
   PubMed Web of Science ®Google Scholar
• Yugawa K, Itoh S, Yoshizumi T, et al. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes. Mod Pathol. 2021;34(4):798–807. .
   PubMed Web of Science ®Google Scholar
• Al Ustwani O, Iancu D, Yacoub R, et al. Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol. 2012;3(2):97–104.
   PubMedGoogle Scholar
• Yang JD, Campion MB, Liu MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2016;63(1):148–158. .
   PubMed Web of Science ®Google Scholar
• Iyer RV, Pokuri VK, Groman A, et al. A multicenter Phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol. 2018;41(7):649–655. .
   PubMed Web of Science ®Google Scholar
• Backen AC, Lopes A, Wasan H, et al. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. Br J Cancer. 2018;119(1):27–35. .
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Fanaian N, Reza J, et al. Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. Cancer Biol Ther. 2018;19(10):887–897. .
   PubMed Web of Science ®Google Scholar
• Gopinathan P, Chiang NJ, Bandaru A, et al. Exploring circulating tumor cells in Cholangiocarcinoma using a novel Glycosaminoglycan probe on a microfluidic platform. Adv Healthc Mater. 2020;9(10):e1901875. .
   PubMed Web of Science ®Google Scholar
• Severino V, Dumonceau JM, Delhaye M, et al. Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology. 2017;153(2):495–504 e498. .
   PubMed Web of Science ®Google Scholar
• Albiin N, Smith IC, Arnelo U, et al. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 2008;49(8):855–862. .
   PubMed Web of Science ®Google Scholar
• Sharif AW, Williams HR, Lampejo T, et al. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB (Oxford). 2010;12(6):396–402. .
   PubMed Web of Science ®Google Scholar
• Nagana Gowda GA, Shanaiah N, Cooper A, et al. Visualization of bile homeostasis using (1)H-NMR spectroscopy as a route for assessing liver cancer. Lipids. 2009;44(1):27–35.
   PubMed Web of Science ®Google Scholar
• Nagana Gowda GA, Shanaiah N, Cooper A, et al. Bile acids conjugation in human bile is not random: new insights from (1)H-NMR spectroscopy at 800 MHz. Lipids. 2009;44(6):527–535.
   PubMed Web of Science ®Google Scholar
• Liang Q, Liu H, Zhang T, et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. Mol Biosyst. 2016;12(2):334–340.
   PubMed Web of Science ®Google Scholar
• Kim KH, Joo J, Park B, et al. Reduced levels of N’-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival. Oncotarget. 2017;8(68):112598–112609. .
   PubMedGoogle Scholar
• Banales JM, Inarrairaegui M, Arbelaiz A, et al. Serum metabolites as diagnostic biomarkers for Cholangiocarcinoma, Hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology. 2019;70(2):547–562. .
   PubMed Web of Science ®Google Scholar
• Macias RIR, Munoz-Bellvis L, Sanchez-Martin A, et al. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(6):1433. .
   Web of Science ®Google Scholar
• Haznadar M, Diehl CM, Parker AL, et al. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1704–1711. .
   PubMed Web of Science ®Google Scholar
• Wang LJ, Zhang KL, Zhang N, et al. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget. 2015;6(21):18631–18640. .
   PubMedGoogle Scholar
• Deng Y, Chen Y. Increased expression of miR-29a and its prognostic significance in patients with cholangiocarcinoma. Oncol Res Treat. 2017;40(3):128–132.
   PubMed Web of Science ®Google Scholar
• Zhou MH, Zhou HW, Liu M, et al. The role of miR-92b in cholangiocarcinoma patients. Int J Biol Markers. 2018;33(3):293–300.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Feng F, Zhu L, et al. Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma. Sci Rep. 2015;5(1):16103. .
   PubMed Web of Science ®Google Scholar
• Zhang RX, Zheng Z, Li K, et al. Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma. Medicine (Baltimore). 2017;96(44):e8267.
   PubMed Web of Science ®Google Scholar
• Li H, Zhou ZQ, Yang ZR, et al. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. Hepatology. 2017;66(1):136–151. .
   PubMed Web of Science ®Google Scholar
• Loosen SH, Lurje G, Wiltberger G, et al. Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma. PLoS One. 2019;14(1):e0210944. .
   PubMed Web of Science ®Google Scholar
• Zhang MY, Li SH, Huang GL, et al. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer. 2015;15(1):64. .
   PubMed Web of Science ®Google Scholar
• Liang Z, Liu X, Zhang Q, et al. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis. 2016;48(10):1227–1232.
   PubMedGoogle Scholar
• Sun C, Zhu J, Wu B, et al. Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis. Cancer Manag Res. 2018;10:2125–2139.
   PubMed Web of Science ®Google Scholar
• Zhou J, Liu Z, Yang S, et al. Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(2):156–162.
   PubMed Web of Science ®Google Scholar
• Liu CH, Huang Q, Jin ZY, et al. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. J Cancer Res Ther. 2018;14(1):220–225. .
   PubMed Web of Science ®Google Scholar
• Salem PES, Ghazala RA, El Gendi AM, et al. The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal. 2020;34(11):e23397.
   PubMed Web of Science ®Google Scholar
• Han HS, Kim MJ, Han JH, et al. Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2020;19(1):41–50. .
   PubMed Web of Science ®Google Scholar
• Shigehara K, Yokomuro S, Ishibashi O, et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011;6(8):e23584. .
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14(9):18925–18958.
   PubMed Web of Science ®Google Scholar
• Andersen RF, Jakobsen A. Screening for circulating RAS/RAF mutations by multiplex digital PCR. Clin Chim Acta. 2016;458:138–143.
   PubMed Web of Science ®Google Scholar
• Wasenang W, Chaiyarit P, Proungvitaya S, et al. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin Epigenetics. 2019;11(1):39.
   PubMed Web of Science ®Google Scholar
• Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology. 2014;60(3):896–907. .
   PubMed Web of Science ®Google Scholar
• Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66(4):1125–1143. .
   PubMed Web of Science ®Google Scholar
• Urban SK, Sanger H, Krawczyk M, et al. Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver Int. 2020;40(12):3103–3116. .
   PubMed Web of Science ®Google Scholar
• Chan-On W, Nairismagi ML, Ong CK, et al., Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 45(12): 1474–1478. 2013.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al., Whole-Genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7(10): 1116–1135. 2017. .
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al., Genomic spectra of biliary tract cancer. Nat Genet. 47(9): 1003–1010. 2015. .
   PubMed Web of Science ®Google Scholar
• Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021;11(2):326-339.
   Google Scholar
• Nepal C, O’Rourke CJ, Oliveira DVNP, Nepal C, O’Rourke CJ, Oliveira D et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology. 2018;68(3):949–963.
   PubMed Web of Science ®Google Scholar
• Namjan A, Techasen A, Loilome W, et al. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ. 2020;8:e10464.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021–1031 e1015.
   PubMed Web of Science ®Google Scholar
• Ruys AT, Groot Koerkamp B, Wiggers JK, Ruys AT, Groot Koerkamp B, Wiggers JK, Klumpen HJ, ten Kate FJ, van Gulik TM. Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2014;21(2):487–500.
   PubMed Web of Science ®Google Scholar
• Jones RP, Bird NT, Smith RA, et al. Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers. Biomark Med. 2015;9(8):763–775.
   PubMed Web of Science ®Google Scholar
• Belkouz A, Labeur TA, Dierks J, et al. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;141:82–94.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6(1):6087.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079. .
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Winter H, Kaisaki PJ, Harvey J, et al. Identification of circulating genomic and metabolic biomarkers in intrahepatic cholangiocarcinoma. Cancers (Basel). 2019;11(12):1895. .
   Web of Science ®Google Scholar
• Fostea RM, Fontana E, Torga G, et al. Recent progress in the systemic treatment of advanced/Metastatic cholangiocarcinoma. Cancers (Basel). 2020;12(9):2599.
   PubMed Web of Science ®Google Scholar
• Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44(12):2768–2773.
   PubMed Web of Science ®Google Scholar
• Vivaldi C, Fornaro L, Ugolini C, et al. HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. Oncologist. 2020;25(10):886–893. .
   Web of Science ®Google Scholar
• Xie Q, Wang L, Zheng S. Prognostic and clinicopathological significance of PD-L1 in patients with cholangiocarcinoma: a meta-analysis. Dis Markers. 2020;2020:1817931.
   PubMed Web of Science ®Google Scholar
• Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099–1109. .
   PubMed Web of Science ®Google Scholar
• Ha H, Nam AR, Bang JH, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7(47):76604–76612. .
   PubMedGoogle Scholar
• Zhang J, Wu Z, Zhang X, et al. Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open. 2020;5(6):e000910. .
   Web of Science ®Google Scholar
• Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013;119(5):993–1003. .
   PubMed Web of Science ®Google Scholar
• Shi XD, Yu XH, Wu WR, et al. Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma. Oncotarget. 2016;7(43):70378–70387. .
   PubMedGoogle Scholar
• Goyal L, Sirard C, Schrag M, et al. Phase I and biomarker study of the Wnt pathway modulator DKN-01 in combination with Gemcitabine/Cisplatin in advanced biliary tract cancer. Clin Cancer Res. 2020;26(23):6158–6167. .
   PubMed Web of Science ®Google Scholar
• Nevi L, Di Matteo S, Carpino G, et al., DCLK1, a putative novel stem cell marker in human cholangiocarcinoma. Hepatology. 71(3): 972–989. 2020.
   PubMed Web of Science ®Google Scholar
• Meadows V, Francis H. DCLK1 in cholangiocarcinoma: is this the biomarker and target we’ve been looking for? Hepatology. 2021;73(1):4-6.
   Google Scholar
• Andrici J, Goeppert B, Sioson L, et al. Loss of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma. Medicine (Baltimore). 2016;95(2):e2491. .
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-Associated cholangiocarcinoma: a multicenter retrospective study. Oncologist. 2017;22(7):804–810.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Bonucci C, et al. PARP inhibitors in biliary tract cancer: a new kid on the block? Medicines (Basel). 2020;7(9): 10.3390/medicines7090054.
   PubMedGoogle Scholar
• Huang XY, Ke AW, Shi GM, et al. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer. 2010;116(23):5440–5451.
   PubMed Web of Science ®Google Scholar
• Lee D, Do IG, Choi K, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25(1):131–139.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kaido T, Okumura S, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl. 2014;20(11):1413–1419.
   PubMed Web of Science ®Google Scholar
• Voron T, Tselikas L, Pietrasz D, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg. 2015;261(6):1173–1183.
   PubMed Web of Science ®Google Scholar
• Okumura S, Kaido T, Hamaguchi Y, et al. Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017;24(4):1037–1045.
   PubMed Web of Science ®Google Scholar
• Yugawa K, Itoh S, Kurihara T, et al. Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma. Am J Surg. 2019;218(5):952–958.
   PubMed Web of Science ®Google Scholar
• Hahn F, Muller L, Stohr F, et al., The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: prognostic marker or hyped parameter? Liver Int. 39(7): 1307–1314. 2019. .
   PubMed Web of Science ®Google Scholar
• Coelen RJ, Wiggers JK, Nio CY, et al. Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford). 2015;17(6):520–528.
   PubMed Web of Science ®Google Scholar
• Van Vugt JLA, Gaspersz MP, Vugts J, et al. Low Skeletal muscle density is associated with early death in patients with perihilar cholangiocarcinoma regardless of subsequent treatment. Dig Surg. 2019;36(2):144–152.
   PubMed Web of Science ®Google Scholar
• Rollins KE, Tewari N, Ackner A, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr. 2016;35(5):1103–1109.
   PubMed Web of Science ®Google Scholar
• Tamura S, Ashida R, Sugiura T, et al. The prognostic impact of skeletal muscle status and bone mineral density for resected distal cholangiocarcinoma. Clin Nutr. 2020; 10.1016/j.clnu.2020.12.011.
   Web of Science ®Google Scholar
• Umetsu S, Wakiya T, Ishido K, et al. Effect of sarcopenia on the outcomes after pancreaticoduodenectomy for distal cholangiocarcinoma. ANZ J Surg. 2018;88(9):E654–E658.
   PubMed Web of Science ®Google Scholar